Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in the Mozambican Population: A Cross-Sectional Serologic Study in 3 Cities, July-August 2020

被引:3
|
作者
Arnaldo, Paulo [1 ]
Mabunda, Nedio [1 ]
Young, Peter Wesley [2 ]
Tran, Tiffany [2 ]
Sitoe, Nadia [3 ]
Chelene, Imelda [3 ]
Nhanombe, Armando [4 ]
Ismael, Nalia [3 ]
Junior, Antonio [5 ]
Cubula, Basilio [6 ]
Inlamea, Osvaldo Frederico [4 ]
Gudo, Eduardo, Jr. [6 ,7 ]
Jani, Ilesh Vinodrai [6 ,7 ]
机构
[1] Inst Nacl Saude, Dept Regulacao & Promocao Invest Saude, Maputo, Mozambique
[2] US Ctr Dis Control & Prevent, Div Global HIV & TB, Maputo, Mozambique
[3] Inst Nacl Saude, Dept Plataformas Tecnol, Maputo, Mozambique
[4] Inst Nacl Saude, Dept Observacao Saude, Maputo, Mozambique
[5] Inst Nacl Saude, Dept Gestao & Coordenacao Invest Saude, Maputo, Mozambique
[6] Inst Nacl Estat, Dept Metodos, Maputo, Mozambique
[7] Inst Nacl Saude, Off Director, Maputo, Mozambique
基金
比尔及梅琳达.盖茨基金会;
关键词
seroprevalence; general population; higher-risk occupational groups; SARS-CoV-2; Mozambique; ANTI-SARS-COV-2 IGG ANTIBODIES; SEROPREVALENCE; HOUSEHOLD; INFECTIONS;
D O I
10.1093/cid/ciac516
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The extent of population exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was uncertain in many African countries during the onset of the pandemic. Methods We conducted a cross-sectional study and randomly selected and surveyed general population and occupational groups from 6 July to 24 August 2020, in 3 cities in Mozambique. Anti-SARS-CoV-2-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies were measured using a point-of-care rapid test. The prevalence was weighted for population (by age, sex, and city) and adjusted for test sensitivity and specificity. Results A total of 21 183 participants, including 11 143 from the general population and 10 040 from occupational groups, were included across all 3 cities. General population seropositivity (IgM or IgG) prevalence was 3.0% (95% confidence interval [CI], 1.0%-6.6%) in Pemba, 2.1% (95% CI, 1.2%-3.3%) in Maputo City, and 0.9% (95% CI, .1%-1.9%) in Quelimane. The prevalence in occupational groups ranged from 2.8% (95% CI, 1.3%-5.2%) to 5.9% (95% CI, 4.3%-8.0%) in Pemba, 0.3% (95% CI, .0%-2.2%) to 4.0% (95% CI, 2.6%-5.7%) in Maputo City, and 0.0% (95% CI, .0%-.7%) to 6.6% (95% CI, 3.8%-10.5%) in Quelimane, and showed variations between the groups tested. Conclusions In the first representative COVID-19 serosurveys in Mozambique, in mid-2020, weighted and assay-adjusted seroprevalence in 3 provincial capitals of anti-SARS-CoV-2 ranged from 0.9% to 3.0%, whereas adjusted prevalence in occupational groups ranged from 0.0% to 6.6% with variation between groups. Exposure to SARS-CoV-2 was extensive during the first pandemic wave, and transmission may have been more intense among occupational groups. These data have been of utmost importance to inform public health intervention to control and respond to the pandemic in Mozambique.
引用
收藏
页码:S285 / S293
页数:9
相关论文
共 50 条
  • [21] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Fatality Rate Among Elderly Danes: A Cross-sectional Study on Retired Blood Donors
    Pedersen, Ole Birger
    Nissen, Janna
    Dinh, Khoa Manh
    Schwinn, Michael
    Kaspersen, Kathrine Agergard
    Boldsen, Jens Kjaergaard
    Didriksen, Maria
    Dowsett, Joseph
    Sorensen, Erik
    Thorner, Lise Wegner
    Larsen, Margit Anita Horup
    Grum-Schwensen, Birgitte
    Saekmose, Susanne
    Paulsen, Isabella Worlewenut
    Frisk, Nanna Lond Skov
    Brodersen, Thorsten
    Vestergaard, Lasse Skafte
    Rostgaard, Klaus
    Molbak, Kare
    Skov, Robert Leo
    Erikstrup, Christian
    Ullum, Henrik
    Hjalgrim, Henrik
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E2962 - E2969
  • [22] Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is not detected in the vagina: A prospective study
    Takmaz, Ozguc
    Kaya, Eren
    Erdi, Burak
    Unsal, Gozde
    Sharifli, Pari
    Agaoglu, Nihat Bugra
    Ozbasli, Esra
    Gencer, Serap
    Gungor, Mete
    PLOS ONE, 2021, 16 (09):
  • [23] Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vaginal swabs of women with acute SARS-CoV-2 infection: a prospective study
    Schwartz, A.
    Yogev, Y.
    Zilberman, A.
    Alpern, S.
    Many, A.
    Yousovich, R.
    Gamzu, R.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (01) : 97 - 100
  • [24] Clinical and Laboratory Findings in Patients With Potential Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection, May-July 2020
    Lee, James T.
    Hesse, Elisabeth M.
    Paulin, Heather N.
    Datta, Deblina
    Katz, Lee S.
    Talwar, Amish
    Chang, Gregory
    Galang, Romeo R.
    Harcourt, Jennifer L.
    Tamin, Azaibi
    Thornburg, Natalie J.
    Wong, Karen K.
    Stevens, Valerie
    Kim, Kaylee
    Tong, Suxiang
    Zhou, Bin
    Queen, Krista
    Drobeniuc, Jan
    Folster, Jennifer M.
    Sexton, D. Joseph
    Ramachandran, Sumathi
    Browne, Hannah
    Iskander, John
    Mitruka, Kiren
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (12) : 2217 - 2225
  • [25] The Promise and Peril of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Monoclonal Antibodies
    Davis, Jennifer M.
    Li, Jonathan Z.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (07) : 1257 - 1259
  • [26] Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    Qu, Jiuxin
    Wu, Chi
    Li, Xiaoyong
    Zhang, Guobin
    Jiang, Zhaofang
    Li, Xiaohe
    Zhu, Qing
    Liu, Lei
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (16) : 2255 - 2258
  • [27] Antibodies in healthcare personnel following severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection
    Bosserman, Rachel E.
    Farnsworth, Christopher W.
    O'Neil, Caroline A.
    Cass, Candice
    Park, Daniel
    Ballman, Claire
    Wallace, Meghan A.
    Struttmann, Emily
    Stewart, Henry
    Arter, Olivia
    Peacock, Kate
    Fraser, Victoria J.
    Budge, Philip J.
    Olsen, Margaret A.
    Burnham, Carey-Ann D.
    Babcock, Hilary M.
    Kwon, Jennie H.
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2022, 2 (01):
  • [28] Post-acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Viral Variant and Vaccination Status: A Multicenter Cross-sectional Study
    Kahlert, Christian R.
    Strahm, Carol
    Gusewell, Sabine
    Cusini, Alexia
    Brucher, Angela
    Goppel, Stephan
    Moller, Elisabeth
    Moller, J. Carsten
    Ortner, Manuela
    Ruetti, Markus
    Stocker, Reto
    Vuichard-Gysin, Danielle
    Besold, Ulrike
    McGeer, Allison
    Risch, Lorenz
    Friedl, Andree
    Schlegel, Matthias
    Vernazza, Pietro
    Kuster, Stefan P.
    Kohler, Philipp
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (02) : 194 - 202
  • [29] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System
    De Felice, Fernanda G.
    Tovar-Moll, Fernanda
    Moll, Jorge
    Munoz, Douglas P.
    Ferreira, Sergio T.
    TRENDS IN NEUROSCIENCES, 2020, 43 (06) : 355 - 357
  • [30] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis
    Charlotte Steenblock
    Vladimir Todorov
    Waldemar Kanczkowski
    Graeme Eisenhofer
    Andreas Schedl
    Ma-Li Wong
    Julio Licinio
    Michael Bauer
    Allan H. Young
    Raul R. Gainetdinov
    Stefan R. Bornstein
    Molecular Psychiatry, 2020, 25 : 1611 - 1617